25 February 2019 - - Finland-based commercial stage molecular diagnostics company Mobidiag Ltd has signed multiple exclusive agreements with international partners for the distribution of its Amplidiag and Novodiag products in Europe and the Middle East, the company said.

Mobidiag has signed exclusive agreements for the distribution of Amplidiag and Novodiag with Helix2 for Greece and Interlab Interautomatika UAB for Latvia and Lithuania. Mobidiag has also signed its first agreement in the Middle East with Ibn Rushd Medical and Scientific Equipment Co. for the distribution of Novodiag in Kuwait.

The agreements are effective immediately and initially in place for a period of two years.

Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics.

Through its Amplidiag and Novodiagsolutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden.